Aggressive B-Cell Non-Hodgkin Lymphoma — Trials

Aggressive B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

400 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 115
Recruiting: 56
Ph III recruiting: 1
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (72)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04512716	Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma	recruiting	Early Phase 1	12	Memorial Sloan Kettering Cancer CenterOTHER	1	Feb 17, 2026	clinicaltrials
NCT07168291	Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma	not yet recruiting	Early Phase 1	3	First Affiliated Hospital Xi'an Jiaotong UniversityOTHER